KEGG   DISEASE: Large-vessel vasculitis
Entry
H01465                      Disease                                
Name
Large-vessel vasculitis
  Subgroup
Giant cell arteritis (GCA) [DS:H01698]
Takayasu arteritis (TAK)
Description
Large vessel vasculitis (LVV) covers a spectrum of primary vasculitides predominantly affecting the aorta and its major branches. Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the two main subtypes. GCA is the most common vasculitis affecting adults aged 50 years or more, while TAK is a rare vasculitis that affects younger individuals mainly under 40 years. Clinical presentations vary from asymptomatic to significant systemic symptoms such as fever, weight loss, and symptoms that result from aortitis and high inflammatory markers; C-reactive protein (CRP); and erythrocyte sedimentation rate (ESR) levels. Glucocorticoids are the mainstay of therapy of LVV. Patients may develop predictable adverse effects from long-term glucocorticoid use.
Category
Immune system disease
Brite
Human diseases in ICD-11 classification [BR:br08403]
 04 Diseases of the immune system
  Nonorgan specific systemic autoimmune disorders
   4A44  Vasculitis
    H01465  Large-vessel vasculitis
Other DBs
ICD-11: 4A44.Y
ICD-10: M31.4 M31.6
MeSH: D013700 D013625
Reference
  Authors
Chatterjee S, Flamm SD, Tan CD, Rodriguez ER
  Title
Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.
  Journal
Curr Cardiol Rep 16:498 (2014)
DOI:10.1007/s11886-014-0498-z
Reference
  Authors
Al-Homood IA
  Title
Tocilizumab: a new therapy for large vessel vasculitis.
  Journal
Clin Exp Med 14:355-60 (2014)
DOI:10.1007/s10238-013-0254-5
LinkDB

» Japanese version

DBGET integrated database retrieval system